Stock Events

Stock Events

Kaleido Biosciences 

$0
10
+$0+0% Friday 21:00

Statistics

Day High
0
Day Low
0
52W High
0.19
52W Low
0
Volume
1,055
Avg. Volume
3,701
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

22NovExpected
Q2 2022
Q3 2022
Q4 2022
Q4 2022
Q1 2024
Q2 2024
Q3 2024
-0.51
-0.34
-0.17
0
Expected EPS
N/A
Actual EPS
N/A

Financials

-8,178.26%Profit Margin
Unprofitable
2017
2018
2019
2020
2021
1.1MRevenue
-90.29MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow KLDO. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Synlogic
SYBX
Mkt Cap19.77M
Synlogic operates in the synthetic biology field focusing on developing therapeutics to improve the gut microbiome, similar to Kaleido's focus on microbiome metabolic therapies.
Serve Robotics
SERV
Mkt Cap814.67M
Seres Therapeutics is directly competing in the microbiome therapeutic space, developing a similar range of products aimed at modifying the microbiome to treat diseases.
Regenxbio
RGNX
Mkt Cap645.07M
REGENXBIO is involved in gene therapy but its interest in developing treatments that could intersect with microbiome health places it as a competitor.
Seres Therapeutics
MCRB
Mkt Cap140.95M
Seres Therapeutics, under ticker MCRB, is focused on microbiome therapeutics for multiple conditions, directly competing with Kaleido's approach to disease treatment.
Axsome Therapeutics
AXSM
Mkt Cap6.74B
Axsome Therapeutics, while primarily focused on CNS disorders, its broad approach to novel therapies could see it venturing into microbiome-related treatments.
AMGEN
AMGN
Mkt Cap160.66B
Amgen, a large biotech firm, has a broad interest in innovative therapeutic areas, including potential interest in the microbiome, making it a competitor due to its size and resources.

About

Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease. It also develops programs for the treatment of multi drug resistant infection, chronic kidney disease, atherosclerotic cardiovascular disease, cardio-metabolic syndrome, immuno-oncology, and inflammatory bowel diseases. The company has collaboration agreements with Institute Gustave Roussy, Washington University, and Janssen. Kaleido Biosciences, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
Show more...
CEO
Dr. Mark A. Wingertzahn Ph.D.
Employees
76
Country
US
ISIN
US4833471000

Listings

OTC Link
US
KLDO

0 Comments

Share your thoughts

FAQ

What is Kaleido Biosciences stock price today?▼
The current price of KLDO is $0 USD — it has increased by +0% in the past 24 hours. Watch Kaleido Biosciences stock price performance more closely on the chart.
What is Kaleido Biosciences stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Kaleido Biosciences stocks are traded under the ticker KLDO.
What is Kaleido Biosciences revenue for the last year?▼
Kaleido Biosciences revenue for the last year amounts to 1.1M USD.
What is Kaleido Biosciences net income for the last year?▼
KLDO net income for the last year is -90.29M USD.
How many employees does Kaleido Biosciences have?▼
As of April 03, 2026, the company has 76 employees.
In which sector is Kaleido Biosciences located?▼
Kaleido Biosciences operates in the Health Care sector.
When did Kaleido Biosciences complete a stock split?▼
Kaleido Biosciences has not had any recent stock splits.
Where is Kaleido Biosciences headquartered?▼
Kaleido Biosciences is headquartered in Lexington, US.